Truist Securities Reiterates Buy Rating on Axsome Therapeutics (AXSM)

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/24/2026

1. DECK
2. RNG
3. WDC
4. BYD
5. SPOT
6. WCN
7. BMY
8. TSCO
9. BE
10. SPY

Go back to Truist Securities Reiterates Buy Rating on Axsome Therapeutics (AXSM)

Axsome Therapeutics (AXSM) PT Raised to $132 at RBC Capital

November 13, 2024 6:44 AM EST

RBC Capital analyst Leonid Timashev raised the price target on Axsome Therapeutics (NASDAQ: AXSM) to $132.00 (from $131.00) while maintaining a Outperform rating.

The analyst comments "This morning, AXSM reported 3Q24 earnings and we had a chance to catch up with management for additional... More